Preventing cardiovascular disease in the 21st century: Therapeutic and preventive implications of current evidence

American Journal of Cardiovascular Drugs

Volumn 6, Issue 2, 2006, Pages 87-101

  Daviglus, Martha L ^a   Lloyd Jones, Donald M ^a   Pirzada, Amber ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LISINOPRIL; MEVINOLIN; NICOTINE DERIVATIVE; NICOTINE GUM; NITRENDIPINE; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; RIMONABANT; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIET; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE POLICY; HEART INFARCTION; HUMAN; HYPOKALEMIA; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIFESTYLE; META ANALYSIS; METABOLIC DISORDER; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; OBESITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING CESSATION; STROKE; SYSTEMATIC REVIEW; SYSTOLIC HYPERTENSION; TOBACCO DEPENDENCE; WEIGHT GAIN; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DRUG THERAPY; DRUG THERAPY, COMBINATION; HUMANS; LIFE STYLE; PRIMARY PREVENTION;

EID: 33645216526     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606020-00003     Document Type: Review

References (113)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics: 2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Committee. Circulation 2006 Feb 14; 113 (6): e85-151
2. American Heart Association. International cardiovascular disease statistics [online]. Available from URL:http://www.americanheart.com/presenter. jhtml?. identifier = 3001008 [Accessed 2005 May 1]
3. Stamler J, Dyer AR, Shekelle RB, et al. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology 1993; 82 (2-3): 191-222
4. Stamler J, Daviglus ML, Garside DB, et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000 Jul 19; 284 (3): 311-8
5. Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001 Jun 25; 161 (12): 1501-8
6. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999 Oct 7; 341 (15): 1097-105
7. Jacobs Jr DR, Adachi H, Mulder I, et al. for the Seven Countries Study Group. Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study. Arch Intern Med 1999 Apr 12; 159 (7): 733-40
8. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five-year follow-up of the seven countries study. JAMA 1995 Jul 12; 274 (2): 131-6
9. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988; 41 (3-4): 155-78
10. Rosengren A, Dotevall A, Eriksson H, et al. Optimal risk factors in the population: prognosis, prevalence, and secular trends; data from Goteborg population studies. Eur Heart J 2001 Jan; 22 (2): 136-44
11. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results: Multiple Risk Factor Intervention Trial Research Group. JAMA 1982; 248 (12): 1465-77
12. Cutler JA, Neaton JD, Hulley SB, et al. Coronary heart disease and all-causes mortality in the Multiple Risk Factor Intervention Trial: subgroup findings and comparisons with other trials. Prev Med 1985; 14: 293-311
13. . Multifactorial trial in the prevention of coronary heart disease: 3. Incidence and mortality results. Eur Heart J 1983 Mar; 4 (3): 141-7
14. Hjermann I, Holme I, Velve KB, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981; II: 1303-10
15. Strandberg TE, Salomaa VV, Naukkarinen VA, et al. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991; 266 (9): 1225-9
16. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984 Jan 20; 251 (3): 351-64
17. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984 Jan 20; 251 (3): 365-74
18. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344 (8934): 1383-9
20. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339 (19): 1349-57
21. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 Oct; 335 (14): 1001-9
22. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 Apr 7; 352 (14): 1425-35
23. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 Nov 16; 333 (20): 1301-8
24. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998 May 27; 279 (20): 1615-22
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002 Jul 6; 360 (9326): 7-22
26. Collaborators CTTC. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78
27. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB, et al. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham heart study. Arch Intern Med 2001 Apr 9; 161 (7): 949-54
28. Mihaylova B, Briggs A, Armitage J, et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 2005 May; 365 (9473): 1779-85
29. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991 Jun 26; 265 (24): 3255-64
30. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997 Sep 13; 350 (9080): 757-64
31. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension: Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16 (12 Pt 1): 1823-9
32. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives. Hypertension 2001; 37: 869-74
33. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000 Mar 11; 355 (9207): 865-72
34. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 Dec 1; 42 (6): 1206-52
35. Pearce KA, Furberg CD, Psaty BM, et al. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens 1998; 11 (5): 618-29
36. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec 18; 288 (23): 2981-97
37. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001; 161: 2661-7
38. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 Sep 12; 317 (7160): 703-13
39. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534-44
40. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324 (7339): 699-703
41. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3): 145-53
42. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
43. Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366 (9489): 907-13
44. Amery A, Birkenhager WH, Brixko P, et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years: EWPHE results: subgroup analysis based on entry stratification. J Hypertens 1986; 4 Suppl. 6: S642-7
45. Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the hypertension in the very elderly trial. J Hypertens 2003 Dec; 21 (12): 2409-17
46. Gueyffier F, Bulpitt C, Boissel J-P, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999 Mar 6; 353 (9155): 793-6
47. Perry HM, Smith WM, McDonald RH, et al. Morbidity and mortality in the systolic hypertension in the elderly program (SHEP) pilot study. Stroke 1989; 20: 4-13
48. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991 Nov 23; 338 (8778): 1281-5
49. Chaudhry SI, Krumholz HM, Foody JM. Systolic hypertension in older persons. JAMA 2004 Sep 1; 292 (9): 1074-80
50. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755-62
51. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58
52. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Washington, DC: US Department of Health and Human Services, 1990. DHHS Publication (CDC) 90-8416
53. Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet 1975 Feb 22; I (7904): 415-20
54. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000 Apr 10; 160 (7): 939-44
55. Hermanson B, Omenn GS, Kronmal RA, et al. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: results from the CASS registry. N Engl J Med 1988 Nov 24; 319 (21): 1365-9
56. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003 Jul 2; 290 (1): 86-97
57. Rea TD, Heckbert SR, Kaplan RC, et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002 Sep 17; 137 (6): 494-500
58. Goldenberg I, Jonas M, Tenenbaum A, et al. Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med 2003 Oct 27; 163 (19): 2301-5
59. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993 Jan 13; 269 (2): 232-6
60. US Department of Health and Human Services. Smoking cessation: information for specialists. Rockville (MD): US Department of Health and Human Services. Agency for Health Care Policy and Research; 1996. DHHS Publication 96-0694
61. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335 (24): 1792-8
62. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29 (7): 1422-31
63. Karnath B. Smoking cessation. Am J Med 2002 Apr 1; 112 (5): 399-405
64. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997 Oct 23; 337 (17): 1195-202
65. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999 Mar 4; 340 (9): 685-91
66. Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation: Agency for Health Care Policy and Research. JAMA 1997 Dec 3; 278 (21): 1759-66
67. Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 2005; 81 (2): 387-95
68. Foulds J, Burke M, Steinberg M, et al. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004; 9 (1): 39-53
69. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995 May 1; 75 (14): 894-903
70. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329 (14): 977-86
71. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366 (9493): 1279-89
72. Colhoun PHM, Betteridge PDJ, Durrington PPN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21; 364 (9435): 685-96
73. Brandle M, Davidson MB, Schriger DL, et al. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 2003 Jun; 26 (6): 1796-801
74. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005 Mar 31; 352 (13): 1293-304
75. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989 Jul 20; 321 (3): 129-35
76. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan 12; 324 (7329): 71-86
77. Lloyd-Jones DM, Leip EP, Larson MG, et al. Novel approach to examining first cardiovascular events after hypertension onset. Hypertension 2005 Jan; 45 (1): 39-45
78. Daviglus ML, Liu K, Yan LL, et al. Body mass index in middle age and health-related quality of life in older age: the Chicago heart association detection project in industry study. Arch Intern Med 2003 Nov 10; 163 (20): 2448-55
79. Yan LL, Daviglus ML, Liu K, et al. BMI and health-related quality of life in adults 65 years and older. Obes Res 2004 Jan; 12 (1): 69-76
80. Ferraro KF, Su YP, Gretebeck RJ, et al. Body mass index and disability in adulthood: a 20-year panel study. Am J Public Health 2002 May; 92 (5): 834-40
81. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995 Apr 1; 122 (7): 481-6
82. Sjostrom CD, Lissner L, Sjostrom L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects. Obes Res 1997; 5: 519-30
83. Sjostrom L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004 Dec 23; 351 (26): 2683-93
84. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995 Jun 15; 141 (12): 1128-41
85. Kolotkin RL, Crosby RD, Williams GR, et al. The relationship between health-related quality of life and weight loss. Obes Res Sep 2001; 9 (9): 564-71
86. Fontaine KR, Barofsky I, Bartlett SJ, et al. Weight loss and health-related quality of life: results at 1-year follow-up. Eat Behav 2004 Jan; 5 (1): 85-8
87. Fontaine KR, Barofsky I, Andersen RE, et al. Impact of weight loss on health-related quality of life. Qual Life Res 1999 May; 8 (3): 275-7
88. Maciejewski ML, Patrick DL, Williamson DF. A structured review of randomized controlled trials of weight loss showed little improvement in health-related quality of life. J Clin Epidemiol 2005 Jun; 58 (6): 568-78
89. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 Apr; 365 (9468): 1389-97
90. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998 Mar; 6 (2): 97-106
91. . Multifactorial trial in the prevention of coronary heart disease: 2. Risk factor changes at two and four years. Eur Heart J 1982 Apr; 3 (2): 184-90
92. Kornitzer M, Rose G. WHO European Collaborative Trial of Multifactorial Prevention of Coronary Heart Disease. Prev Med 1985; 14: 272-8
93. Holme I, Hjermann I, Helgeland A, et al. The Oslo Study: diet and antismoking advice: additional results from a 5-year primary preventive trial in middle-aged men. Prev Med 1985 May; 14 (3): 279-92
94. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002 Dec 18; 288 (23): 2998-3007
95. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000 Apr 19; 283 (15): 1967-75
96. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003 Jun 28; 326 (7404): 1419
97. Franklin BA, Kahn JK, Gordon NF, et al. A cardioprotective "polypill"? Independent and additive benefits of lifestyle modification. Am J Cardiol 2004 Jul 15; 94 (2): 162-6
98. The Hypertension Detection and Follow-up Program Cooperative Research Group. Mortality findings for stepped-care and referred-care participants in the Hypertension Detection and Follow-up Program, stratified by other risk factors. Prev Med 1985; 14: 312-35
99. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis 1978 Apr; 31 (4): 201-306
100. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999 Dec 1; 282 (21): 2012-8
101. Daviglus ML, Stamler J, Pirzada A, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA 2004 Oct 6; 292 (13): 1588-92
102. Daviglus ML, Liu K, Greenland P, et al. Benefit of a favorable cardiovascular risk factor profile in middle age with respect to Medicare costs. N Engl J Med 1998 Oct 15; 339 (16): 1122-9
103. Daviglus ML, Liu K, Pirzada A, et al. Favorable cardiovascular risk profile in middle age and health-related quality of life in older age. Arch Intern Med 2003 Nov 10; 163 (20): 2460-8
104. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000 Dec 19; 102 (25): 3137-47
105. Manolio T, Chen J, Sorlie P, et al. US Trends in prevalence of low coronary risk, National Health and Nutrition Examination Surveys (NHANES). Circulation 2004; 109: e71-144
106. National Center for Health Statistics. Health, United States 2004: with chartbook on trends in the health of Americans [online]. Available from URL: http: // www.cdc.gov/nchs/hus.htm [Accessed 2005 Jul 1]
107. Miura K, Greenland P, Stamler J, et al. Relation of vegetable, fruit, and meat intake to 7-year blood pressure change in middle-aged men: the Chicago Western Electric Study. Am J Epidemiol 2004 Mar 15; 159 (6): 572-80
108. Stamler J, Elliott P, Dennis B, et al. INTERMAP: background, aims, design, methods, and descriptive statistics (nondietary). J Hum Hypertens 2003 Sep; 17 (9): 591-608
109. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997 Apr 17; 336 (16): 1117-24
110. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N Engl J Med 2001 Jan 4; 344 (1): 3-10
111. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004 Sep 22; 292 (12): 1433-9
112. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003 Aug 20; 290 (7): 891-7
113. Robinson JG, Maheshwari N. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol 2005 Feb 1; 95 (3): 373-8